RSS
|
Login
|
Register
Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Issue Archive
Events
Awards
Webcasts
Surveys
Directories
PMD
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Medical Education Review
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
Home
>
News
> UC Davis medical center debates pooled CME fund
CME Report
UC Davis medical center debates pooled CME fund
December 01, 2006
Print
Email
Reprint
Font Size:
A
|
A
|
A
The UC Davis medical center's executive committee is set to decide on several recommendations, one a ban on all gifts that includes payments from industry for participating in eCME. Davis is debating a pooled CME fund.
From the December 2006 Issue of MMM
Most Popular
Thomson Reuters names five most promising Q1 drugs
Pharma donors favor Obama
Harry and Louise having second thoughts on healthcare
Manhattan Research names top product sites for docs
Stanford prohibits direct commercial CME sponsorship
GSK to make grant info public
UCB cuts 2,000 jobs, re-tools as a specialty company
Vioxx trial described as marketing stunt
Medical Economics overhauls editorial team
AMM honors top journal ads
Most Emailed
The End of CME as We Know It
Abbott launches Crohn's disease podcasts
Verispan acquired by data rival SDI
AstraZeneca teams up with Abbott on Crestor co-promote
'Fully Engaged' docs more open to influence
UCB cuts 2,000 jobs, re-tools as a specialty company
Stanford prohibits direct commercial CME sponsorship
Surprise! Massachusetts gift ban is back
Changing Channels
Manhattan Research names top product sites for docs
Most Recent
UCB cuts 2,000 jobs, re-tools as a specialty company
GfK drops TNS bid
Stanford prohibits direct commercial CME sponsorship
Manhattan Research names top product sites for docs
Medical Economics overhauls editorial team
GSK to make grant info public
AMM honors top journal ads
Vioxx trial described as marketing stunt
Harry and Louise having second thoughts on healthcare
Thomson Reuters names five most promising Q1 drugs
Popular Tags
Advertising
Agency
Approval
Awards
Brand
Business
Clinical trial
Consumer
Continuing medical education (CME)
Creative
Digital
Direct marketing
Direct to consumer (DTC)
Education & Awareness
FDA
Government
Launch
Marketing & Communications
Marketing Research
Media
Pharmaceutical
Professional
Promotion
Regulatory
Sales force
Home
|
News
|
Features
|
Events
|
Surveys
|
Lists
|
Directories
|
Jobs
|
About Us
|
Contact Us
|
Subscribe
|
Newsletters
|
PMD
|
Advertise
|
Editorial Advisory Board
|
RSS